The AGENT DCB STANCE trial pits the drug-coated balloon (DCB) head-to-head against percutaneous coronary intervention (PCI) treatment with drug-eluting stents (DES) and/or balloon angioplasty – in patients with de novo (previously untreated) coronary lesions.

Boston Scientific’s prospective, multi-center, open-label, 1:1 randomized controlled study includes more than 1,600 patients. It has a primary endpoint defined as target lesion failure at 12 months.

In addition to evaluating de novo small vessel treatment with Agent DCB, the trial also examines the use of the device in patients with bifurcations and long lesions.